indazoles has been researched along with Hypercoagulability in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Evans, CE; Grover, SP; Humphries, J; Lyons, OT; Modarai, B; Patel, AP; Patel, AS; Saha, P; Smith, A; Waltham, M | 1 |
| Crijns, HJ; De Boer, HC; De Jong, AM; Kamphuisen, PW; Kuiper, M; Lau, DH; Linz, D; Lumeij, S; Maass, AH; Rienstra, M; Schotten, U; Spronk, HM; Ten Cate, H; Van Gelder, IC; van Hunnik, A; van Zonneveld, AJ; Verheule, S; Zeemering, S | 1 |
| Bair, AH; Bycott, P; Chan, S; Joy, AA; Kim, S; Liau, KF; Lluch, A; Rosbrook, B; Rugo, HS; Soulieres, D; Stopeck, AT; Verma, S | 1 |
1 trial(s) available for indazoles and Hypercoagulability
| Article | Year |
|---|---|
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypertension; Imidazoles; Indazoles; Middle Aged; Mucositis; Neoplasm Proteins; Neutropenia; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Taxoids; Thrombophilia | 2011 |
2 other study(ies) available for indazoles and Hypercoagulability
| Article | Year |
|---|---|
Antiangiogenic therapy inhibits venous thrombus resolution.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Animals; Axitinib; Blood Coagulation; Capillary Permeability; Collagen; Estradiol; Imidazoles; Indazoles; Macrophages; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Neutrophils; Thrombophilia; Vena Cava, Inferior; Venous Thrombosis | 2014 |
Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
Topics: Analysis of Variance; Animals; Antithrombins; Atrial Fibrillation; Cell Proliferation; Dabigatran; Female; Fibrinolytic Agents; Fibroblasts; Fibrosis; Goats; Heart Atria; Indazoles; Mice, Transgenic; Nadroparin; Peptide Hydrolases; Pyrroles; Quinazolines; Rats; Receptors, Thrombin; Thrombin; Thrombophilia; Urea | 2017 |